All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-12-13T23:09:28.000Z

Naval Daver | ASH 2018 | Key highlights of immunotherapeutic agents for AML at ASH 2018

By Naval Daver, Stephanie Hill
Featured
Naval Daver
Dec 13, 2018
Share:

Bookmark this article

Naval Daver from the MD Anderson Cancer Center, Houston, US, provided updates on data presented at the 2018 American Society of Hematology meeting, on immunotherapeutic agents for acute myeloid leukemia. 

Key highlights of immunotherapeutic agents for AML at ASH 2018

More about...
AMG 330ASH 2018CD123 CAR-TCD33 CAR-T

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 79 days left ...

Related articles

Add bookmark

Bispecific antibodies in lymphoma, myeloma and acute myeloid leukemia

Bispecific antibodies and chimeric antigen receptor T-cell therapy, are being investigated as agents to reduce the tumor load pre-SCT or post-SCT, with the aim of decreasing...

Oct 18, 2019
Add bookmark

Bispecific antibodies in lymphoma, myeloma and acute myeloid leukemia

Bispecific antibodies and chimeric antigen receptor T-cell therapy, are being investigated as agents to reduce the tumor load...

Oct 18, 2019
Add bookmark

ASH 2018 | AMG 330, a BiTE® construct, in patients with relapsed/refractory acute myeloid leukemia

Preliminary data of AMG 330 dosed up to 480 μg/d provide encouraging early evidence of tolerability and anti-leukemic activity in heavily pre-treated...

Dec 7, 2018
Add bookmark

ASH 2018 | AMG 330, a BiTE® construct, in patients with relapsed/refractory acute myeloid leukemia

Preliminary data of AMG 330 dosed up to 480 μg/d provide encouraging early evidence of tolerability...

Dec 7, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox